Table 2.
Proportion of participants with incident composite CV event (ASCVD or HF) and HF across 2017 ACC/AHA BP guideline recommended treatment groups stratified by biomarker status
| Participant Groups | Number of participants | Incident composite CV events (%) | Incident HF (%) | |
|---|---|---|---|---|
| Not recommended to receive anti-HTN medication | Normal BP | 7,038 | 267 (3.8) | 85 (1.2) |
| Elevated BP or low-risk stage 1 HTN, both biomarker (−) | 2,005 | 92 (4.6) | 17 (0.9) | |
| Elevated BP or low-risk stage 1 HTN, any biomarker (+) | 955 | 105 (11.0) | 41 (4.3) | |
| Recommended to receive anti-HTN medication | High-risk stage 1 HTN or stage 2 HTN (BP <160/100 mm Hg), both biomarker (−) | 1,380 | 109 (7.9) | 28 (2.0) |
| High-risk stage 1 HTN or stage 2 HTN (BP <160/100 mm Hg), any biomarker (+) | 1,199 | 181 (15.1) | 67 (5.6) | |
| Stage 2 HTN (BP ≥160/100 mm Hg) | 410 | 71 (17.3) | 23 (5.7) |
Normal BP: <120/80 mm Hg; elevated BP: 120–129/<80 mm Hg; stage 1 HTN: 130–139/80–89 mm Hg; stage 2 HTN: ≥140/90 mm Hg; high-risk stage 1 HTN was defined by the presence of any of the following: PCE-estimated 10-year ASCVD risk ≥10%, diabetes mellitus, estimated GFR <60 mL/min per 1.73 m2, or age ≥65 years with systolic BP ≥130 mmHg; in the absence of all of these risk factors, individuals with stage 1 HTN were classified as low-risk; both biomarker (−): hs-cTnT <6 ng/L and NT-proBNP <100 pg/mL; any biomarker (+): hs-cTnT ≥6 ng/L and/or NT-proBNP ≥100 pg/mL. Number at risk used to estimate the proportion of participants with incident HF is similar to or slightly lower than the total number of participants in each group.
Composite CV event = non-fatal MI, non-fatal stroke, HF, or CV death.
Abbreviations: anti-HTN = anti-hypertensive; ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CV = cardiovascular; GFR: glomerular filtration rate; HF = heart failure; hs-cTnT = high-sensitivity cardiac troponin T; HTN = hypertension; MI = myocardial infarction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PCE = pooled cohort equation